Amendments to the Claims

1. (Currently Amended) A compound of the formula:

wherein R represents C_1 - C_{20} alkyl, C_2 - C_6 alkenyl, C_1 - C_6 alkylaryl C_1 - C_6 alkyl-aryl, C_1 - C_6 alkyl- C_3 - C_{10})cycloalkyl, C_1 - C_6 alkyl- C_1 - C_6 alkyl-pyrrolidine, C_1 - C_6 alkyl-piperidine, C_1 - C_6 alkyl-morpholine or a pharmaceutically acceptable salt thereof.

- 2. (Original) A compound according to claim 1 wherein R represents C_1 - C_{10} alkyl.
- 3. (Original) A compound according to claim 2 wherein R represents 2-ethyl butyl, isobutyl, 3-methyl butyl, decyl, or ethyl.
- 4. (Original) A compound according to claim 3 wherein R represents 2-ethyl butyl,
 - 5. (Original) A compound according to claim 3 wherein R represents isobutyl.
- 6. (Original) A compound according to claim 3 wherein R represents 3-methyl butyl.
 - 7. (Original) A compound according to claim 3 wherein R represents decyl.
 - 8. (Original) A compound according to claim 3 wherein R represents ethyl.
- 9. (Original) A compound which is (3*S*,4a*R*,6*R*,8a*R*)-6-[2-(1H-Tetrazol-5-yl)-ethyl] -1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid 2-ethyl-butyl ester, or a pharmaceutically acceptable salt thereof.

- 10. (Original) A compound according to claim 9 wherein the pharmaceutically acceptable salt is a trifluoroacetate salt.
- 11. (Original) A compound which is (3*S*,4a*R*,6*R*,8a*R*)-6-[2-(1H-Tetrazol-5-yl)-ethyl] -1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid isobutyl ester, or a pharmaceutically acceptable salt thereof.
- 12: (Original) A compound according to claim 11 wherein the pharmaceutically acceptable salt is a trifluoroacetate salt.
- 13. (Original) A compound which is (3*S*,4a*R*,6*R*,8a*R*)-6-[2-(1H-Tetrazol-5-yl)-ethyl] -1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid 3-methyl butyl ester, or a pharmaceutically acceptable salt thereof.
- 14. (Original) A compound according to claim 13 wherein the pharmaceutically acceptable salt is a trifluoroacetate salt.
- 15. (Original) A compound which is (3*S*,4a*R*,6*R*,8a*R*)-6-[2-(1H-Tetrazol-5-yl)-ethyl] -1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid decyl ester, or a pharmaceutically acceptable salt thereof.
- 16. (Original) A compound according to claim 15 wherein the pharmaceutically acceptable salt is a trifluoroacetate salt.
- 17. (Original) A compound which is (3*S*,4a*R*,6*R*,8a*R*)-6-[2-(1H-Tetrazol-5-yl)-ethyl] -1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid ethyl ester, or a pharmaceutically acceptable salt thereof.
- 18. (Previously Amended) A compound according to claim 17 wherein the pharmaceutically acceptable salt is a hydrochloride salt.
- 19. (Original) A compound which is (3*S*,4a*R*,6*R*,8a*R*)-6-[2-(1H-Tetrazol-5-yl)-ethyl] -1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid ethyl ester hydrochloride monohydrate.

- 20. (Original) A pharmaceutical composition, which comprises a compound as claimed in Claim 1 and a pharmaceutically acceptable diluent or carrier.
 - 21. (Cancelled)
- 22. (Currently Amended) A method of treating pain, which comprises administering to a patient an effective amount of a compound of the formula:

wherein R represents C_1 - C_{20} alkyl, C_2 - C_6 alkenyl, C_1 - C_6 -alkylaryl C_1 - C_6 alkyl-aryl, C_1 - C_6 alkyl- C_3 - C_{10})cycloalkyl, C_1 - C_6 alkyl- C_1 - C_6 alkyl-pyrrolidine, C_1 - C_6 alkyl-piperidine, C_1 - C_6 alkyl-morpholine or a pharmaceutically acceptable salt thereof.

23. (Currently Amended) A method of treating migraine, which comprises administering to a patient an effective amount of a compound of the formula:

wherein R represents C_1 - C_{20} alkyl, C_2 - C_6 alkenyl, C_1 - C_6 -alkylaryl C_1 - C_6 alkyl-aryl, C_1 - C_6 -alkyl- C_3 - C_{10})cycloalkyl, C_1 - C_6 alkyl- C_1 - C_6 alkyl- C_1 - C_6 alkyl-pyrrolidine, C_1 - C_6 alkyl-piperidine, C_1 - C_6 alkyl-morpholine or a pharmaceutically acceptable salt thereof.

- 24. (Cancelled)
- 25. (Cancelled)
- 26. (New) A pharmaceutical composition, which comprises a compound as claimed in Claim 9 and a pharmaceutically acceptable diluent or carrier.

- 27. (New) A pharmaceutical composition, which comprises a compound as claimed in Claim 11 and a pharmaceutically acceptable diluent or carrier.
- 28 (New) A pharmaceutical composition, which comprises a compound as claimed in Claim 13 and a pharmaceutically acceptable diluent or carrier.
- 29. (New) A pharmaceutical composition, which comprises a compound as claimed in Claim 15 and a pharmaceutically acceptable diluent or carrier.
- 30. (New) A pharmaceutical composition, which comprises a compound as claimed in Claim 17 and a pharmaceutically acceptable diluent or carrier.
- 31. (New) A method of treating pain, which comprises administering to a patient an effective amount of a compound as claimed in Claim 9.
- 32. (New) A method of treating pain, which comprises administering to a patient an effective amount of a compound as claimed in Claim 11.
- 33. (New) A method of treating pain, which comprises administering to a patient an effective amount of a compound as claimed in Claim 13.
- 34. (New) A method of treating pain, which comprises administering to a patient an effective amount of a compound as claimed in Claim 15.
- 35. (New) A method of treating pain, which comprises administering to a patient an effective amount of a compound as claimed in Claim 17.
- 36. (New) A method of treating migraine, which comprises administering to a patient an effective amount of a compound as claimed in Claim 9.
- 37. (New) A method of treating migraine, which comprises administering to a patient an effective amount of a compound as claimed in Claim 11

- 38 (New) A method of treating migraine, which comprises administering to a patient an effective amount of a compound as claimed in Claim 13.
- 39 (New) A method of treating migraine, which comprises administering to a patient an effective amount of a compound as claimed in Claim 15.
- 40. (New) A method of treating migraine, which comprises administering to a patient an effective amount of a compound as claimed in Claim 17.